NurExone competed in the Healthcare category at the BOLD Awards VII, standing out among seven other leading companies in the field. The selection was made by a panel of judges composed of global market leaders, innovators, and change-makers. The principal judge for the Healthcare category was Mr. Ben Beckley, CEO of RevHealth. Ben
Exosomes are nanoscale extracellular vesicles (EVs) secreted by nearly all mammalian cells. Originally believed to be cellular debris, they are now understood to be sophisticated messengers carrying proteins, lipids, and nucleic acids that mediate intercellular communication. Their role in immune modulation, tissue repair, and signaling has made them attractive candidates
The Company has signed a consulting agreement with Dr. Lars Bärfacker, an experienced medicinal chemist and former Principal Research Scientist at Bayer AG, to support aspects of NurExone’s European scientific and strategic initiatives. Dr. Bärfacker has more than two decades of experience in drug discovery and innovation and has contributed
TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announced today its participation in two international conferences taking place in March 2026. Dr. Lior Shaltiel, PhD, Chief Executive Officer
Toronto, Ontario and Haifa, Israel–(Newsfile Corp. – February 10, 2026) – NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system injuries, today announced results from an independent proteomic analysis conducted at the Technion – Israel
TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has
TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced new laboratory data demonstrating that its proprietary exosomes can significantly reduce inflammatory activity compared to untreated cells and cells treated with a commercially available exosome
TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-biotechnology company developing exosome-based therapies for central nervous system injuries, today announced meaningful progress in its long-term clinical-readiness strategy. The Company has begun the process of
